Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis

OBJECTIVES: To evaluate the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis (RA) and an inadequate response or intolerance to conventional synthetic disease-modifying antirheumatic drugs. METHODS: In this phase III study, patients were randomise...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:RMD Open
Main Authors: Emery, Paul, Blanco, Ricardo, Maldonado Cocco, Jose, Chen, Ying-Chou, Gaich, Carol L, DeLozier, Amy M, de Bono, Stephanie, Liu, Jiajun, Rooney, Terence, Chang, Cecile Hsiao-Chun, Dougados, Maxime
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2017
Assuntos:
Rheumatoid Arthritis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5372156/
https://ncbi.nlm.nih.gov/pubmed/28405473
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2016-000410
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados